Jul 21, 2021 - Health

Anthem still determining what to do with Aduhelm

Bob Herman

Anthem's profits dropped in Q2, but still tallied $1.8 billion. Photo: Michael Nagle/Bloomberg via Getty Images

Anthem is "going to continue to evaluate" the data around Aduhelm, the controversial Alzheimer's drug, before making final insurance coverage decisions, CEO Gail Boudreaux told investors Wednesday.

Why it matters: Several other Blue Cross Blue Shield insurers have said they will not cover Aduhelm, but Anthem is still weighing the options like its competitor UnitedHealth, which also wants to wait and see what the federal government says.

By the numbers: Anthem's revenue in the second quarter increased 16% year over year, totaling almost $34 billion.

Profit was down 21% from the same period last year, hitting $1.8 billion. Similar to UnitedHealth, more patients got care this year whereas the pandemic kept most people indoors and away from doctors last year.
Anthem now insures 44.3 million people, up 4.4% from a year ago. But most of those gains came in its private Medicare and Medicaid plans. Anthem continues to lose people in job-based plans.

Add Axios on Google

Anthem still determining what to do with Aduhelm

What to read next